Adalimumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Adalimumab and local guidelines before prescribing.

Biologic DMARD (anti-TNF)

Mechanism

Monoclonal antibody that binds and neutralises TNF-alpha.

Uses

Rheumatoid, psoriatic and juvenile arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, psoriasis, uveitis.

Dosing

Side effects

Infections, injection-site reactions, headache; reactivated TB, demyelination, lupus-like syndrome, heart failure worsening.

Interactions

Avoid with other biologics; live vaccines contraindicated; methotrexate reduces antibody formation.

Contraindications and cautions

Active infection, moderate to severe heart failure, demyelinating disease

Monitoring

TB and hepatitis B screen; FBC; signs of infection

Pregnancy and breastfeeding

Limited data; specialist advice

Renal and hepatic impairment

No dose adjustment

Overdose and reversal

No antidote; stop if infection

Special advice

Screen for TB and hepatitis B; check varicella status; stop and seek advice during serious infection; avoid in moderate to severe heart failure.

More from the textbook: uses, cautions and other points
Where it is discussed in the book